RNA interference (RNAi) is a sequence-specific gene silencing mechanism with therapeutic potential against many human pathogens. To obtain a durable therapeutic effect, stable transduction of target cells with for instance a lentiviral vector that expresses a short hairpin (shRNA) inducer of the RNAi pathway is necessary. Apart from the intended therapeutic effect, this treatment can induce negative effects on cell proliferation via off-target effects. A careful evaluation of the transduced cells is required to develop a safe gene therapy approach. Stably transduced cells are usually selected by expression of the enhanced green fluorescent protein (GFP) marker. In this study we show that the mixed transduction culture, containing both transduced GFP þ and untransduced GFP À cells, can simply be passaged to score the GFP þ /GFP À ratio by longitudinal flow cytometric analysis as a measure of the negative impact of the RNAi treatment on the cellular proliferation rate. We show that this assay is sensitive, easy to use and internally controlled for assessing subtle effects on cell proliferation of lentiviral transduction and transgene expression.
INTRODUCTION
RNA interference (RNAi) is an evolutionary conserved mechanism induced by double-stranded RNA, leading to sequence-specific gene silencing at the post-transcriptional level. 1 RNAi can be induced transiently by transfecting target cells with small interfering RNAs (siRNAs) or stably by intracellular expression of short hairpin RNAs (shRNAs). Both strategies can be exploited for therapeutic purposes against a wide variety of diseases or microbial pathogens such as viral infections. 2 --6 Both viral RNA and cellular transcripts that encode cofactors necessary for viral replication can be targeted. 7 Especially for the attack on viruses that cause a persistent infection the preferred method is the generation of stable knockdown cells, in which constitutive expression of the antiviral shRNAs is achieved by vector transduction. In particular, lentiviral vectors have been very successful because they are able to transduce many different cell types, both actively dividing, and quiescent cells, in which the viral genome is stably integrated in the host cell DNA. A marker, which usually encodes for antibiotic resistance or a fluorescent marker protein like the green fluorescent protein (GFP), can be used to select the transduced cells.
An important consideration when developing gene therapeutic strategies based on RNAi is the potential impact on the physiology and viability of the transduced cells. RNAi can have adverse effects on cellular properties and affect cell growth for several reasons. First, off-target effects of the shRNA on an unspecified mRNA with partial sequence complementarity can affect cell growth in an unpredictable manner. 8 Second, overexpression of shRNA molecules can saturate components of the RNAi pathway, and thus disturb normal cellular gene regulation by microRNAs. 9, 10 Third, shRNA overexpression can trigger innate immune responses such as the interferon cascade. 11 --13 Fourth, targeting of a cellular protein that functions as cofactor for virus replication can affect cell growth. Caution is particularly warranted in case of stable gene knockdown, as subtle differences in cell growth rates can have a major impact on biological assays in diverse in vitro settings. The use of a stably integrating retroviral or lentiviral vector can cause additional adverse effects due to genome integration, for example, disruption of the regulation of local cellular genes. Obviously, in vivo RNAi and in fact any transgene application should put an emphasis on addressing such putative adverse effects on cell physiology and cell growth. Gross cell growth defects can be monitored using a variety of assays. Staining with trypan blue and other dyes, such as 4',6-diamidino-2-phenylindole or Hoechst 33342, can distinguish between live and dead cells. To calculate the cell doubling time, the increase in number of cells can be measured over time, either by direct counting of the cells (manually or automatically) or indirectly by reporter luciferase assays that measure the ATP content of metabolically active cells. However, there is a need for a simple assay to score for more subtle cell growth effects. We explored the option to maintain the mixed culture obtained after gene transduction that consists of transduced GFP þ and non-transduced GFP À cells. The GFP þ /GFP À ratio can simply be evaluated by Fluorescence-activated cell sorting (FACS) analysis over time, which allows one to score minor cell growth defects as a gradual loss of the percentage GFP þ cells. This assay is based on the competitive cell growth between transduced and non-transduced cells. We compared this competitive cell growth (CCG) assay to established methods of counting cells (both by FACS and with a hemacytometer), the MTT assay and a commercially available ATP bioluminescence assay. We demonstrate that the CCG assay provides a sensitive, internally controlled and simple procedure.
RESULTS

Design of the competitive cell growth assay
To establish an easy and sensitive assay to monitor changes in proliferation of transduced cells we developed the CCG assay. This assay is based on the assumption that direct competition between transduced and untransduced cells will be the most sensitive and controlled way to compare growth differences. In fact, both untransduced and transduced cells will be present in the culture after transduction and this crude transduction mixture can thus be used directly in the CCG assay. This provides a direct the advantage over other proliferation assays, for which selection of the transduced cells is necessary before one can determine the impact on cell growth (Figure 1) .
To critically test the competitive CCG assay we used several shRNA-expressing lentiviral vectors. Two control lentiviral vectors were used; SHC1 lacking a shRNA cassette (empty vector) and SHC2 expressing a scrambled shRNA molecule that has no identifiable mRNA target in human cells. Three shRNA constructs were selected that target specific cellular mRNAs and that were previously demonstrated---based on visual inspection of long-term cultures---to have a small effect on cell proliferation (shRNA1), an intermediate effect (shRNA2) or a severe effect (shRNA3). We currently do not know whether this toxicity is due to downregulation of the specific mRNA target or due to an unspecific off-target effect. However, the impact on cell physiology was reproducible, which made them excellent candidates to validate the CCG assay.
Lentiviral vectors encoding these shRNAs were generated and used to stably transduce the SupT1 T-cell line. A fixed amount of SupT1 cells was transduced with 0.1, 1 or 10 ml of the lentivirus stocks. The titer of all vectors used in this study was comparable (data not shown). These cultures were maintained as normal SupT1 cell lines (1 in 10 split twice weekly) over a period of 26 days. Two days post transduction one usually determines the percentage of transduced, GFP-positive cells, which can be FACSsorted for further experimentation. However, the CCG assay is performed on the raw transduction mixture of transduced and untransduced cells. This cell mixture is simply maintained and periodically scored for the percentage of GFP-positive cells.
The percentage of GFP-expressing cells in the control cell lines SHC1 and SHC2 was stable over time, indicating a lack of toxicity in the transduced cells (Figure 2a, upper panels) . These results also indicate that integration of the lentiviral vector into the host cell genome (SHC1) and the induction of the RNAi pathway (SHC2) have no effect on the cell proliferation capacity in this setting. However, a steady reduction in the percentage of GFP-expressing cells was observed over time when a vector encoding a shRNA against specific targets was used. The reduction was small in the case of the least toxic shRNA1 and increased when more toxic shRNAs were expressed (Figure 2a, lower panels) . This reduction was observed with all three lentiviral vector inputs, thus no careful titration is needed to score toxic effects.
When one wants to determine the quantitative differences, the growth defect of the GFP þ cells can be calculated based on the known doubling time of SupT1 cells, the GFP þ /GFP À cell ratio at the start and end of the experiment and the time period. For each cell line and for each lentiviral vector input, we calculated the percentage growth rate defect based on a doubling time of 1.1 days for SupT1 cells. This doubling time is the average of values scored in the four alternative cell proliferation assays (Figure 5b , lower panels). The most prominent differences were observed for shRNA3 with 10 ml lentiviral vector input. The shRNA3 cells proliferated 21±6% slower than the SupT1 control cells in the same culture ( Figure 2b ). For shRNA1 and shRNA2 also significant differences were measured when compared with SupT1 cells, with 11 ± 1% and 11 ± 0.5% reduction in growth rate, respectively. With a lower lentiviral vector input, the shRNA-expressing cells again exhibited a reduced proliferation rate, but this difference is only significant for the most toxic shRNA3. No growth rate differences were observed between SupT1 and the two control cell lines SHC1 and SHC2 (Figure 2b ).
The CCG assay is compatible with high-throughput screening. When many transduced cultures have to be analyzed in parallel, one simply maintains the transduction mixtures in a 24-or even a 96-wells format. Many flow cytometers are equipped with a plate reader, thus allowing the screening of hundreds of cultures within an hour. For instance, we analyzed 19 shRNA-expression lentiviral vectors, including the controls SHC1 and SHC2 at a low (1 ml) and high (100 ml) transduction level ( Figure 3) . The shRNAs are shown in increasing order of cytotoxicity, shRNA4 being the least cytotoxic with a 4% decrease in proliferation rate compared with CCG assay GFP selection Expansion Cell proliferation assays
Limiting dilution Expansion Figure 1 . The CCG assay versus other cell proliferation assays. The CCG assay follows the percentage of transduced GFP þ cells over time, and is performed on the crude transduction mixture, providing fast and internally controlled results. Other cell proliferation assays requires the selection of pure GFP þ transduced cells, for example, by FACS sorting and subsequent expansion. In some cases, one even needs to generate clonal cell lines by limiting dilution and by expanding the clonal cells before proliferation assays can be performed.
SupT1
, and shRNA20 showing the biggest decline in proliferation rate; growing 23% slower than SupT1. These cell lines were analyzed once every week, with a maximal assay time of 1 h.
Decrease in percentage of GFP-expressing cells is due to outgrowth of non-transduced cells
We reasoned that the decrease in percentage of GFP-expressing cells results from outgrowth of untransduced cells, but it cannot formally be excluded that GFP-positive cells loose transgene expression over time. Such transgene silencing has been reported on many occasions. 14, 15 Although the polymerase III-driven shRNA cassettes seem to be rather sturdy, 16 the polymerase II-driven GFP unit may be affected. To distinguish between these two possibilities, a new batch of cells was transduced with shRNA3 using a high lentiviral vector input. After sorting, this culture was 99.8% GFP-positive, but also in this culture the percentage of GFPpositive cells decreased after 40 days. Clonal transduced cells were generated by limiting dilution on day 48 post transduction and the parental culture was frozen. The clonal cells and the thawed parental culture were analyzed for GFP expression over a period of 13 days, which corresponds to 68 --99 days post transduction for the clonal cells and days 61 --74 for the parental culture. FACS analysis on day 13 of the experiment indicated the expected loss of GFP-positive cells in the parental culture, but no loss of GFP expression was observed in the two clonal cells (Figure 4) . We therefore conclude that the decrease in percentage of GFP-expressing cells in the CCG assay is due to outgrowth of untransduced over transduced cells.
Comparison of the CCG assay with other well-established methods A variety of methods can be used to measure the impact of a gene therapy treatment on cell proliferation. Here we compared the new CCG assay with several well-established methods. Cells transduced with 100 ml lentiviral vector were FACS sorted for GFP expression and subsequently expanded. This directly reveals an advantage of the CCG assay, in which these extra steps are not required (Figure 1 ). Five different cell proliferation assays, including the CCG test, were performed in parallel over a period of 5 days.
The CCG assay was performed with a mix of the sorted cells in a 1:1 ratio with untransduced SupT1 cells. A sample was analyzed daily by flow cytometry to determine the decrease in GFP percentage (Figure 5a ). The percentage of GFP þ cells remained constant in the control cultures SHC1 and SHC2, but decreased due to shRNA1, shRNA2 and shRNA3 expression. The percentage difference in growth rates was compared with SHC1 ( Figure 5b , upper panel). The difference in growth rates was significantly higher for shRNA1, shRNA2 and shRNA3, with shRNA1 being the least toxic, with a 9±2% slower growth rate. A 34±5% slower growth rate was measured for shRNA3 when compared with SHC1 mixed culture.
Of the four alternative proliferation assays, the easiest way to measure cell proliferation in culture is by counting the number of cells over time. This can be performed manually, using a hemacytometer in combination with trypan blue staining of dead cells in the culture sample ('manual counting' in Figure 5a ). Although easy to use, this is a laborious method that is not applicable for high-throughput screening. We also determined the number of live cells by flow cytometry ('automated counting' in Figure 5a ). A fixed volume (100 ml) of cell culture was analyzed daily. This method allows one to distinguish live from dead cells and the increase in number of cells provides a measure of cell proliferation. Furthermore, the procedure is suitable for highthroughput experiments.
Some proliferation assays measure the increase in metabolic activity due to an increase in cell number. The most well-known test is the MTT assay. 17 The yellow dye MTT is conversed to purple formazan crystals when added to the cell culture and the absorbance can be quantified with a spectrophotometer. This conversion only takes place when reductase enzymes are active, thus only when live cells are present in the culture. The more live cells in a culture, the more purple formazan is produced, resulting in higher absorbance values over time ('MTT' in Figure 5a ). We also tested an ATP bioluminescence assay that measures the ATP content of a sample, which is an indicator for metabolically active cells. 18 A sample is taken daily and mixed with the assay reagent containing luciferase, and the light signal is measured in a luminometer. The luciferase signal is proportional to the ATP A single representative curve is shown for each of the four assays (Figure 5a, lower panels) . To compare the proliferation assays, the doubling time of each cell line was calculated based on two experiments and normalized to SupT1, of which the doubling time was set at 1 (Figure 5b ). The doubling times of the cell lines show a clear trend where shRNA3 is causing a cell growth delay, but these differences were not significant except for the manual counting method. No significant differences in cell growth could be scored for the weak and intermediate toxic shRNA1 and shRNA2. Thus, the CCG assay is clearly most sensitive as significant cytopathic effects were reproducibly measured for all three shRNAs.
DISCUSSION
In this study we describe a new method to assess small changes in the proliferation rate of cells treated with a viral vector harboring a fluorescent selection marker, for example, GFP. This method, the CCG assay, is based on scoring the differences in proliferation rates between transduced and untransduced cells in the same culture. As transduced cells express GFP in addition to a (therapeutic) transgene, the loss in percentage of GFP-positive cells over time is a direct measure of the cell proliferation defect of transduced cells compared with untransduced cells.
The CCG assay has some advantages over other well-established cell proliferation assay. First of all, the raw transduction mixture can be tested directly, that is, no extra steps of selection and expansion of transduced cells are necessary. Importantly, the CCG assay is internally controlled as it is performed with a mixture of untransduced and transduced cells. The CCG assay is user-friendly, as no precise ratio of transduced over untransduced cells is required. There is an obvious lower limit of the assay, below B5% GFP þ cells, to allow a reliable measurement of an altered GFP þ / GFP À ratio (data not shown). Too high transduction efficiencies may be dangerous in the sense that multiple vector integrations may occur, which will result in increased shRNA expression levels. Indeed, such increased toxicity was scored for high-level transduction of the shRNAs and even the SHC2 scrambled shRNA control exerted some toxic effects when overexpressed. We scored such effects when over 95% of the cells were transduced.
A major advantage of the CCG assay is its extreme sensitivity. We measured a significant decrease in cellular proliferation rates when toxic shRNAs are expressed, compared with the control cell lines SHC1 and SHC2. A 10% reduction in proliferation rate can be significantly detected in the CCG assay, and although all tested proliferation assays show similar shRNA toxicity, only manual counting revealed a significant toxic effect of the most toxic shRNA3. In the CCG assay even smaller growth defects can be observed. Although some of these values may not be statistically significant, the fact that the percentage of GFP þ cells decreases over time is a strong indication of a minor proliferation defect. For some of the shRNA cassettes we have been able to correlate cell growth problems as measured in vitro with the CCG test with in vivo results in humanized mouse models (unpublished results).
The CCG assay is not limited to human T-cell lines or to shRNA research. Other cell types can be used, both suspension and adherent cells and even primary cells, at least when a certain level of proliferation is observed in 5 days. In case of primary cells, one should keep in mind that a culture of primary cells often consists of different sub-populations, each with a different transducibility. If GFP measurement over time can be combined with FACS analysis of cell-type-specific markers, one could even monitor growth of the different cell types in a single assay. It remains important to include proper controls, such as an empty lentiviral vector. In this study we scored for the impact of shRNA expression on cell growth, but any transduction event can be assessed in the CCG assay, for instance cellular problems due to vector integration or transgene expression. Not only a decrease in cell proliferation can be measured but also an increase in percentage of GFP þ cells over time, which would indicate an increased cell proliferation rate. This may reveal oncogenic changes in the transduced cells. In exceptional cases the shRNA could have an off-target impact on the GFP reporter, which could be misinterpreted as cellular toxicity. However, such an effect will cause a reduced GFP intensity, which was not observed for the clonal cells (Figure 4 ). An increase in percentage of GFP þ cells may be observed when the transgene provides a selective advantage under the culture conditions applied. One should be cautious when the transgene can have an effect on untransduced bystander cells in the mixed culture. We used lentiviral vectors to stably transduce the shRNA cassette, but other vector systems, integrating (retroviral) or nonintegrating (e.g., adenovirus or adeno-associated virus), are compatible with the transient CCG test. Therefore, we propose that the CCG assay is a welcome addition to the existing array of proliferation assays, especially when one is interested in scoring subtle effects on cell growth due to stable transgene expression.
MATERIALS AND METHODS
DNA constructs
Lentiviral vector pLKO.1 constructs expressing shRNA were from the MISSION TRC-Hs 1.0 library, 19 including the negative control constructs SHC001 and SHC002 (renamed as SHC1 and SHC2), were obtained as bacterial clones from Sigma-Aldrich (St Louis, MO, USA). Plasmid DNA was extracted using the Nucleobond Midiprep columns according to the manufacturer's instructions (Macherey-Nagel, Dü ren, Germany).
Sequences for shRNA1, 2 and 3 are, respectively, as follows:
The pLKO. cloned into pLKO.1, cut with the same enzymes to replace the puromycinresistant marker. GFP expression is under the control of the pGK promoter that was already present in pLKO.1 construct The resulting plasmid was named pLKO.1 --GFP. All constructs were verified by restriction enzyme analysis and GFP expression.
Cell culture
Human embryonic kidney 293T (HEK293T) adherent cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. Human SupT1 T cells were grown in suspension in RPMI medium (Invitrogen) supplemented with 10% fetal calf serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. Cell lines were cultured in a humidified chamber at 37 1C and 5% CO 2 .
Lentiviral vector production and transduction Lentiviral vectors were produced as previously described. 16 In short, HEK293T cells were co-transfected with shRNA-expressing construct and the packaging plasmids pRSV-Rev, pMDLg/pRRE and pVSV-G using Lipofectamine 2000 (Invitrogen). One day after transfection the medium was refreshed and the following day the supernatant was collected. The virus-containing supernatant was centrifuged, filtered (0.45 mm) and aliquots were stored at À80 1C. A sample was taken for CA-p24 enzyme-linked immunosorbent assay to monitor lentiviral particle production. SupT1 cells were seeded in a 24-wells plate (1 Â 10 5 cells per well). Lentiviral vector (0.1, 1, 10 or 100 ml) was added and incubated overnight. Excess virus was washed away on the second day.
Generation of clonal transduced cell lines
For the generation of clonal cell lines, the lentiviral-transduced cells were serially diluted (10-fold) in conditioned medium (filter-sterilized supernatant from a 3-day culture of SupT1 cells, culture medium RPMI þ 10% fetal calf serum). For every dilution, a 96-wells plate was seeded and incubated for 2 weeks in a humidified chamber at 37 1C and 5% CO 2 . When a plate showed cell growth in equal to or less than 30 of the 96 wells, the positive cultures were considered to represent clonal cell lines, based on Poisson distribution.
Flow cytometry
Cell samples for analysis of GFP expression were spun down at 1500 g for 4 min and the cell pellet was gently resuspended in 200 ml FACS solution (phosphate-buffered saline þ 2% FCS). Flow cytometry analyses were performed on a FACS Canto cytofluorometer (BD Biosciences, Franklin Lakes, NJ, USA). Live cells were discriminated from cell debris and dead cells based on physical parameters (forward-and side-light scatter). Fluorescence background levels were set with untransduced and unstained cells. . Statistical analysis shows significant slower proliferation rate in the case of shRNA1, shRNA2 and shRNA3 when compared with the SHC1 mixed culture. With the growth curves of two independent experiments the relative doubling times for each cell line was calculated. Doubling time of SupT1 was set at 1. When compared with SupT1 in the manual counting assay, shRNA3 has a significant increased doubling time. Results are from two independent experiments, performed in triplicates (manual and automated counting) or in sixfolds (MTT and ATP bioluminescence assays). *Po0.1, **Po0.01 and ***Po0.001.
Cell proliferation assays
For the different proliferation assays, cells were FACS-sorted based on GFP expression. The sorted cell lines and SupT1 cells were seeded in 96-wells plates at a density of 1 Â 10 5 cells per ml in 100 ml per well. The proliferation of these cell lines was tested in four proliferation assays, which were performed in triplicates for automated and manual counting and in sixfold for the MTT and luciferase assays. In parallel the CCG assay was performed by mixing the sorted cultures with untransduced SupT1 cells and by following the GFP percentage over a period of 5 days.
The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) was used as follows. A 100-ml sample was taken daily for each cell line in sixfolds over a period of 5 days and stored at À20 1C until measurement following manufacturer's instructions. In brief, 20 ml sample was mixed 1:1 with CellTiter-Glo reagent in a white half-well 96-wells plate for 10 min. The luciferase signal, which is directly proportional to the amount of metabolically active cells in the sample, was measured on a Glomax luminometer (Promega).
For automated cell counting, daily samples were taken. Cells clusters in the culture were disrupted by gently pipetting up and down and 100 ml of cell suspension was transferred to a FACS tube containing 200 ml FACS buffer. Each sample was counted for 20 s with identical FACS settings. The increase in number of live cells over time in the sample is a direct measure of cell proliferation. For manual counting, a 10 ml sample was taken daily and mixed 1:1 with trypan blue. A total volume of 10 ml was loaded into a hemacytometer (Hycor, Garden Grove, CA, USA) and cells were counted in nine squares (0.1 mm 3 ) to determine the number of cells per ml. The MTT assay was performed as described earlier. 17 Each day for 5 days 30 ml MTT was added to the wells of a single plate for 4 h at 37 1C. The wells on the edge of the plate were excluded to prevent variation due to evaporation and wells filled only with medium served as a negative control. After incubation 100 ml was carefully removed from each well and 100 ml dissolving solution (0.1% Triton-X, 4 mM HCl in isopropanol) was added to dissolve the formazan crystals. Formazan absorbance was measured with an ELx808 microplate reader (Biotek Instruments, Winooski, VT, USA) at 550 nm and background levels were scored at 650 nm.
Calculations and statistical analysis
To calculate the defect in cell growth rate measured in the CCG assay, with the assumption that the decrease in the ratio of GFP þ to GFP À cells over time is exponential, the following formula was used:
where G d is the calculated growth defect, T d(GFP þ ) and T d(GFPÀ) are the doubling times in days of the GFP þ and GFP À cells, respectively, x is the number of days over which the decrease in GFP percentage is measured, and y is calculated as %GFP þ /%GFP À at the time point x divided by the %GFP þ /%GFP À at the time point 0. CCG experiments were performed on at least two occasions, each in triplicates. Cell counting with FACS and a hemacytometer were also performed in triplicate and in sixfolds for the MTT and ATP bioluminescence assays. All data were corrected for variation between experiments using Factor Correction. 21 For cell counting, MTT and ATP bioluminescence assays, doubling times were calculated based on exponential growth curve fitting of the cell growth curves and represented as mean doubling time±s.d. To test whether doubling times were significantly different from the control culture (SupT1), one-way analysis of variance was performed with 95% confidence interval. For the CCG assay, a Student's t-test was performed on the percentage difference in doubling time, and compared with SHC1, again with 95% confidence interval.
